← Browse by Condition
Medical Condition

fabry disease

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for fabry disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — fabry disease Clinical Trials

How many clinical trials are currently recruiting for fabry disease?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for fabry disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for fabry disease?
fabry disease research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a fabry disease clinical trial?
Eligibility criteria for fabry disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 3
1
Top Sponsors
Chiesi Farmaceutici S.p.A. 2 trials
Yonsei University 1 trial
UniQure Biopharma B.V. 1 trial

Recruiting Clinical Trials

NCT07235709
Recruiting
Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study
Enrollment
25 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT06270316 Phase 1, Phase 2
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
Enrollment
20 pts
Location
United States
Sponsor
UniQure Biopharma B.V.
View Trial →
NCT06941025
Recruiting
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Enrollment
10 pts
Location
United States, Germa...
Sponsor
Chiesi Farmaceutici S.p.A.
View Trial →
NCT06328608 Phase 2, Phase 3
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Enrollment
22 pts
Location
United States, Austr...
Sponsor
Chiesi Farmaceutici S.p.A.
View Trial →

Related Conditions

pregnancy (1) pregnancy complications (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology